HBM Partners
VC Fund
Zug, Switzerland
HBM Partners is a VC fund in Zug focused on Biotechnology and Health Care. HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through allstages of development, focusing on adding value by leveraging its experience and HBM's world-wide network in the industry. Investments usually range between $5 million to $50 million.
- Total investments:
- 59
- Last investment:
- Lead investor:
- 15%
- Fund size:
- $105M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries HBM Partners invests in
Stages HBM Partners invests in
Countries HBM Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $7.7M–$125M
- Series C
- $2.5M–$111M
Investment Focus
Industry
- Biotechnology 31 (53%)
- Health Care 19 (32%)
- Medical 17 (29%)
- Pharmaceutical 13 (22%)
- Therapeutics 12 (20%)
Stage
- Series B 13 (22%)
- Series C 10 (17%)
- Funding Round 9 (15%)
- Convertible Note 6 (10%)
- Series A 5 (8%)
Country
- United States 23 (39%)
- Germany 6 (10%)
- Switzerland 4 (7%)
- Canada 2 (3%)
- Austria 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andreas Wicki
Founder & CEO
|
Founder & CEO | Total investments: 7 | Find email | |
Chandra Leo
Partner
|
Partner | Total investments: 5 | Find email | |
Erwin Troxler
CFO
|
CFO | Total investments: 0 | Find email | |
Axel Bolte
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Saeid Akhtari
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AtaiBeckley
|
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. | $149.5M / Post-IPO Equity / Oct 16, 2025 | |
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $75M / Series D / Aug 23, 2023 | |
Upstream Bio
|
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses. | $200M / Series B / Jun 08, 2023 | |
Farmalisto
|
Farmalisto is an online retailer that sells a range of products and services to its clients.The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers.Farmalistowas launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City.Websites:https://www.farmalisto.com.mxhttps://www.farmalisto.com.co | $4.3M / Convertible Note / Jun 02, 2023 | |
connectRN
|
connectRN connects the nursing community with opportunities - and each other - to build a supportive and thriving network. The company was founded in 2014 and is based in Waltham, Massachusetts, United States. | $750K / Convertible Note / May 31, 2023 | |
Antiva Biosciences
|
Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco. | $53M / Series E / Apr 27, 2023 | |
Shape Memory Medical
|
Shape Memory Medical Inc is a medical device company based in Santa Clara, California, founded to commercialize innovative medical devices based on Shape Memory Polymer (SMP) materials that were developed at Texas A&M University and Lawrence Livermore National Laboratory. The company is dedicated to developing innovative therapeutic solutionsfor peripheral vascular, cardiovascular, and neurovascular markets.Shape Memory Medical's device is the first to introduce an FDA-cleared medical device utilizing shape memory polymer (SMP) technology to a vascular market, enabling physicians to improve patient care. The Shape Memory Medical team has extensive experience with the SMP foam technology and the commercialization of medical devices. | $600K / Convertible Note / Apr 21, 2023 | |
Sphingotec GmbH
|
SphingoTec is a biomaker company that develops and markets in vitro diagnostic solutions for novel and proprietary blood-based protein biomarkers. They also develop microtiter plates, which are a standard tool in analytical research and diagnostic testing laboratories. They develop biomakers to address diagnostically underserved critical careconditions such as acute kidney injury, sepsis, and acute heart failure. | $1.6M / Series B / Mar 14, 2023 | |
Genalyte
|
Genalyte, Inc. is a life sciences company developing and commercializing innovative next-generation multiplexing technology. Genalyte has developed a new approach to immunodetection using silicon chip manufacturing methods. Its Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies andantigens or hybridization of nucleic acids. | $13M / Series C / Mar 07, 2023 | |
|
Upstream Bio
|
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. They are clinical-stage monoclonal antibodies that inhibit the TSLP receptor, a validated target located upstream of various signaling cascades that influence a range of immune cells that are important in common and unusual illnesses. | $8M / Series A / Feb 10, 2023 | |
| See all 59 investments → | |||
Co-Investors
HBM Healthcare Investments
24 deals together
Catalys Pacific
8 deals together
InterWest Partners
5 deals together
RTW Investments
5 deals together
Samsara BioCapital
5 deals together
Advanced Technology Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does HBM Partners invest in?
HBM Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 59 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is HBM Partners's check size?
HBM Partners typically joins rounds of $7.7M–$125M at Series B and $2.5M–$111M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HBM Partners participates in.
How do I contact HBM Partners?
Public channels for HBM Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at HBM Partners?
The team at HBM Partners includes Andreas Wicki (Founder & CEO), Chandra Leo (Partner) and Erwin Troxler (CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
